Yousif Capital Management LLC Has $903,000 Stock Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Yousif Capital Management LLC reduced its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 1.3% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 43,270 shares of the biopharmaceutical company’s stock after selling 592 shares during the period. Yousif Capital Management LLC’s holdings in Catalyst Pharmaceuticals were worth $903,000 as of its most recent filing with the SEC.

Several other hedge funds have also bought and sold shares of CPRX. Pacer Advisors Inc. lifted its position in Catalyst Pharmaceuticals by 5.4% during the fourth quarter. Pacer Advisors Inc. now owns 2,955,508 shares of the biopharmaceutical company’s stock worth $61,681,000 after acquiring an additional 151,495 shares during the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of Catalyst Pharmaceuticals by 4.5% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,167,743 shares of the biopharmaceutical company’s stock worth $23,215,000 after purchasing an additional 50,804 shares during the period. abrdn plc bought a new position in shares of Catalyst Pharmaceuticals during the fourth quarter worth approximately $10,115,000. JPMorgan Chase & Co. increased its holdings in shares of Catalyst Pharmaceuticals by 9.1% during the third quarter. JPMorgan Chase & Co. now owns 408,261 shares of the biopharmaceutical company’s stock worth $8,116,000 after purchasing an additional 33,888 shares during the period. Finally, Jane Street Group LLC increased its holdings in shares of Catalyst Pharmaceuticals by 245.4% during the third quarter. Jane Street Group LLC now owns 401,908 shares of the biopharmaceutical company’s stock worth $7,990,000 after purchasing an additional 285,564 shares during the period. 79.22% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Catalyst Pharmaceuticals

In other news, Director Molly Harper sold 17,500 shares of the company’s stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $22.00, for a total transaction of $385,000.00. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Gary Ingenito sold 12,000 shares of the company’s stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $22.72, for a total transaction of $272,640.00. Following the transaction, the insider now owns 51,391 shares in the company, valued at $1,167,603.52. This represents a 18.93 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 79,500 shares of company stock worth $1,754,140 over the last quarter. Company insiders own 11.00% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the stock. Stephens assumed coverage on shares of Catalyst Pharmaceuticals in a research note on Monday, November 18th. They issued an “overweight” rating and a $35.00 price objective on the stock. Baird R W raised shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a research note on Monday, February 3rd. Bank of America reissued a “buy” rating and issued a $30.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Thursday, January 9th. StockNews.com cut shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 11th. Finally, Robert W. Baird began coverage on shares of Catalyst Pharmaceuticals in a research note on Tuesday, February 4th. They set an “outperform” rating and a $28.00 target price on the stock. Nine equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Catalyst Pharmaceuticals has an average rating of “Buy” and a consensus target price of $32.25.

Catalyst Pharmaceuticals Stock Up 0.0 %

CPRX stock opened at $23.27 on Friday. The firm has a market cap of $2.78 billion, a price-to-earnings ratio of 19.72, a PEG ratio of 3.46 and a beta of 0.80. Catalyst Pharmaceuticals, Inc. has a 12-month low of $13.49 and a 12-month high of $24.64. The company’s fifty day simple moving average is $22.18 and its 200 day simple moving average is $21.09.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.